Amneal Pharmaceuticals (NASDAQ:AMRX) Given New $25.00 Price Target at JPMorgan Chase & Co.

Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price boosted by JPMorgan Chase & Co. from $24.00 to $25.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research analysts have also weighed in on AMRX. UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Zacks Research raised Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Barclays boosted their price target on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 17th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Finally, Oppenheimer began coverage on Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $22.75.

Amneal Pharmaceuticals Stock Down 1.3%

AMRX opened at $19.95 on Wednesday. The company has a debt-to-equity ratio of 5.61, a current ratio of 1.87 and a quick ratio of 1.44. The stock has a market capitalization of $6.37 billion, a price-to-earnings ratio of 47.50, a price-to-earnings-growth ratio of 2.36 and a beta of 1.24. The business has a 50-day moving average of $19.26 and a two-hundred day moving average of $15.85. Amneal Pharmaceuticals has a 12 month low of $11.14 and a 12 month high of $21.68.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.03. The company had revenue of $862.68 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%. On average, research analysts expect that Amneal Pharmaceuticals will post 0.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the sale, the director directly owned 210,252 shares in the company, valued at approximately $3,708,845.28. This trade represents a 19.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jason Daly sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 413,016 shares of company stock worth $7,216,567 over the last quarter. 17.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in shares of Amneal Pharmaceuticals by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,831,581 shares of the company’s stock worth $76,900,000 after acquiring an additional 536,048 shares during the last quarter. Ethic Inc. acquired a new position in shares of Amneal Pharmaceuticals in the third quarter worth about $427,000. Pictet Asset Management Holding SA boosted its holdings in Amneal Pharmaceuticals by 4.4% in the third quarter. Pictet Asset Management Holding SA now owns 638,040 shares of the company’s stock valued at $12,887,000 after purchasing an additional 26,810 shares during the last quarter. Kestra Advisory Services LLC purchased a new position in Amneal Pharmaceuticals in the third quarter valued at about $304,000. Finally, Oregon Public Employees Retirement Fund increased its holdings in Amneal Pharmaceuticals by 5.9% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 41,400 shares of the company’s stock worth $834,000 after purchasing an additional 2,300 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue was about $863 million and adjusted diluted EPS was $0.26, above analyst estimates of roughly $0.23–$0.24. Adjusted EBITDA was $207 million. Amneal third-quarter results
• Positive Sentiment: Amneal raised its full-year 2026 guidance, citing growth in Affordable Medicines and Specialty. Articles highlighted biosimilars and specialty launches as expanding the company’s growth drivers, supporting the improved outlook. Q3 results and raised guidance
• Positive Sentiment: JPMorgan raised its price target to $25 from $24 and maintained an Overweight rating, signaling continued analyst optimism. JPMorgan rating and price target
• Negative Sentiment: Despite the adjusted profit, Amneal reported a GAAP net loss of $22 million and diluted GAAP loss per share of $0.06. The company also disclosed asset impairment charges, which investors may view as a drag on reported results. Asset impairment charges

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.